Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Roundup: FDA Inspecting McNeil Plants, Hi-Tech Gets Another Chance Against FTC

This article was originally published in The Tan Sheet

Executive Summary

J&J CFO Domnic Caruso says FDA officials are at McNeil’s three plants subject to a consent decree; an appeals court says a lower court should allow Hi-Tech to present additional evidence for weight loss claims.

You may also be interested in...



Hi-Tech Hunts Growth As FTC Picks Up Scent On Disputed Weight Loss Claims

FTC asks a federal court to re-instate a contempt order stemming from Hi-Tech Pharmaceuticals’ misleading claims for weight loss supplements that an appellate court overturned. Hi-Tech, meanwhile, argues for recusal of the judge who found the firm in contempt and ordered two executives to jail.

Hi-Tech Hunts Growth As FTC Picks Up Scent On Disputed Weight Loss Claims

FTC asks a federal court to re-instate a contempt order stemming from Hi-Tech Pharmaceuticals’ misleading claims for weight loss supplements that an appellate court overturned. Hi-Tech, meanwhile, argues for recusal of the judge who found the firm in contempt and ordered two executives to jail.

AER experiment gets OMB approval

A proposed experiment by FDA's Center for Drug Evaluation and Research designed to identify statements that most effectively convey OTC and Rx AER data to consumers has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995, FDA announces. The agency proposed the experiment, "Toll-Free Number for Consumer Reporting of Drug Product Side Effects: Comprehension" following a proposed rule in 2004 requiring all OTCs approved under an NDA or ANDA to add a toll-free number and other statement to product labeling for AER purposes (1"The Tan Sheet" April 26, 2004, p. 14)...

Topics

Related Companies

UsernamePublicRestriction

Register

PS107664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel